

## Disclosures

### Personal Commercial (7)

| Company Name         | Relationship Category                            | Compensation Level | Topic Area(s)      |
|----------------------|--------------------------------------------------|--------------------|--------------------|
| <i>Self</i>          |                                                  |                    |                    |
| CSL Behring          | Research/Research Grants                         | None (\$0)         | Prevention         |
| CSL Behring          | Consultant Fees/Honoraria                        | Modest (< \$5,000) | Prevention         |
| Horizon Therapeutics | Consultant Fees/Honoraria                        | Modest (< \$5,000) | Prevention         |
| Johnson & Johnson    | Consultant Fees/Honoraria                        | Modest (< \$5,000) | Prevention         |
| JP Morgan            | Consultant Fees/Honoraria                        | Modest (< \$5,000) | General Cardiology |
| Quest                | Research/Research Grants<br>† Cholesterol Efflux | None (\$0)         | Prevention         |
| Raydel               | Consultant Fees/Honoraria                        | Modest (< \$5,000) | Prevention         |

### Additional Personal Commercial Disclosures for Education Activities (0)

No disclosures on record

### Personal Organizational or Other Non-Commercial (1)

| Non-Commercial Entity Name | Relationship Category    | Compensation Level       | Topic Area(s)                |
|----------------------------|--------------------------|--------------------------|------------------------------|
| <i>Self</i>                |                          |                          |                              |
| NIH                        | Research/Research Grants | Significant (>= \$5,000) | Prevention Vascular Medicine |

### Clinical Trial Enroller (2)

| Trial Name    | Trial Sponsor         | Trial Funding Source |
|---------------|-----------------------|----------------------|
| ACCLAIM-Lp(a) | Eli Lilly and Company |                      |
| LpaHorizon    | Novartis              |                      |

### Institutional Financial Decision-Making Role (0)

No disclosures on record

### Expert Witness Testimony (0)

No disclosures on record

† Commercial Funding Source | ‡ Trial Name

## Agreement

### Certified Education Attestation | Signed on 12/11/2024

URL for full agreement: <http://disclosures.acc.org/Public/Definition/CertifiedEducationAttestationAgreement>

### Confidentiality, Disclosure and Assignment Agreement | Signed on 12/11/2024

URL for full agreement: <http://disclosures.acc.org/Public/Definition/ConfidentialityDisclosureandAssignmentAgreement>

### Embargo | Signed on 12/11/2024

URL for full agreement: <http://disclosures.acc.org/Public/Definition/EmbargoAgreement>

### On-Going Obligation Agreement | Signed on 12/11/2024

ACC is committed to ensuring balance, independence, objectivity, and scientific rigor in their governance, programmatic, educational, chapter, and other activities. Fulfilling this commitment depends on member and public confidence in the College's integrity and objectivity. The College recognizes that the activities of College members in their practice, research, and other volunteer and private endeavors could lead to the development of conflicts of interest. Therefore, the College has established a Disclosure Policy and conflict of interest management process as appropriate. All members involved in College governance, including all committees and task forces, programmatic, certified educational, chapter, and other activities must provide complete, timely, accurate, and signed disclosure statements. Compliance with this process is mandatory for participation in College activities.